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Abstract
Background: Duchenne muscular dystrophy (DMD) is an X-linked recessive muscle-wasting disease caused by a
mutation in the DMD gene. The aim of this study was to identify a de novo mutation of the DMD gene in the
family of a 9-month-old Chinese male patient, as well as to describe the phenotypic characteristics of this patient.
Results: The patient was suspected to suffer from DMD according to physical examination, biochemical analyses,
and electromyogram. We identified a duplication of exons 4–42 in DMD gene with targeted exome sequencing
and multiplex ligation-dependent probe amplification (MLPA). In addition, the patient’s mother was a carrier of the
same mutation.
Conclusions: We identified a de novo duplication of exons 4–42 in a patient with early stage DMD. The discovery
of this mutation may provide insights into future investigations.
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Background
Duchenne muscular dystrophy (DMD), an X-linked
recessive muscle-wasting disease, is caused by a mutation
in the DMD gene that encodes the dystrophin protein
[1, 2]. As the most common muscle disease in children,
the incidence of DMD is 1 in 3500 live male births [3].
DMD is a progressive neuromuscular disease characterized
by pseudohypertrophy in the calf muscle and the Gowers’
sign [4]. Patients with DMD are usually first diagnosed
before 5 years of age and many pass away due to respiratory
or cardiac failure at around 20 years of age [5, 6].
DMD is the largest known human gene encompassing
2.2 Mb of nucleotides that contain 79 exons [6]. The large
size of the gene increases its susceptibility to mutations as
evidenced by the one-third of de novo mutations identi-
fied in DMD [4]. Furthermore, intragenic deletions repre-
sent 65–70% of all mutations, while duplications are
found in 7% of patients and the remaining mutations are
either point mutations or small deletions/insertions [4].
Diagnosis of the DMD mainly depends on the genetics
of the patient [4]. Recent studies showed that targeted
exome sequencing is a powerful tool for diagnosis of
Mendelian diseases [7], This is especially true for
patients who are at the early stage of a disease and show
no obvious clinical manifestation. Targeted exome
sequencing can screen for mutations in a panel of many
genes that are implicated in various inherited diseases,
making it a tremendously useful technique for identifica-
tion of disease associated mutations.
However, targeted exome sequencing is relatively less
powerful in testing large intragenic rearrangements. In the
case of DMD, deletions found in most patients are
followed by duplications, therefore, multiplex PCR, which
can detect up to 98% of deletion, was considered as the
standard diagnostic method [8]. Nevertheless, multiplex
PCR is not the ideal technique for identifying duplications
and female carriers due to the presence of a normal copy
of the DMD gene [3]. Fortunately, the introduction of a
dosimetry method based on multiplex ligation-dependent
probe amplification (MLPA) has improved the discovery
of large intragenic rearrangements [8].
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In this study, we implemented a combination of MLPA
with targeted exome sequencing to comprehensively
screen for large fragment duplications in the DMD gene
in a 9-month-old Chinese male patient. Using this
method, we were able to identify a novel duplication of
exons 4–42 in the DMD gene.
Methods
Patient characteristics
This study was in compliance with the Declaration of
Helsinki and was approved by the Ethics Committee of
The Second Affiliated Hospital and Yuying Children’s
Hospital of Wenzhou Medical University. A 9-month-old
male patient was referred to our hospital in 2015. Written
informed consent was obtained from his statutory guardian.
Patients’ initial symptoms and complaints was diarrhea. The
patient received a comprehensive examination including
physical examination, biochemical analyses and elec-
tromyogram. Detailed family history was obtained from
the patient, and peripheral blood samples were collected.
MLPA
MLPA analysis was performed using SALSA MLPA kit
P034/P035 (MRC-Holland, Amsterdam, the Netherlands)
kit according to manufacturer’s instructions. The MLPA
samples consisted of approximately 100 ng of genomic
DNA. Denaturation, hybridization, ligation and amplifica-
tion were performed with ABI 2720 PCR thermal cycler.
The PCR amplification was performed under the follow-
ing conditions: 33 cycles of 95 °C for 30 s, 60 °C for 30 s
and 72 °C for 60 and a final extension step at 72 °C for
20 min to allow for adequate probe hybridization with the
two sets of probes. Results were analyzed using Coffalyser
9.4 (MRC Holland).
Targeted exome sequencing
Genomic DNA was extracted from blood samples using
a DNA Extraction kit (TIANGEN, Beijing) according to
the manufacturer’s instructions. The coding exons of
131 genes related to inherited diseases were selected and
captured with a GenCap custom enrichment kit
(MyGenostics, Beijing) as previously described [9].
Genomic DNA was fragmented and mixed with GenCap
probe (MyGenostics, Beijing) for PCR amplification and
hybridization. After washing with MyOne beads (Life
Technology), the sample was resuspended in binding
buffer, transferred along with MyOne beads, and rotated
for 1 h. Then, DNA was eluted with Buffer Elute,
followed by amplification in post-capture. The enriched
libraries were sequenced on a IlluminaSolexaHiSeq 2000
sequencer. After removing PCR duplicates with Picard
program, the clean reads were aligned with SOAP
aligner program [10] according to human genome
parameters (hg19). Then, we identified SNPs using the
SOAPsnp program, realigned the reads by BWA, and
determined the deletions or insertions (InDels) with the
GATK software [11]. After annotation of the identified
InDels and SNPs using the Exome-assistant program
(http://122.228.158106/exomeassistant), candidate SNPs,
InDels and the short read alignments were viewed by
Magic Viewer [12] To determine pathogenicity, four
algorithms, PolyPhen, SIFT, Mutationtaster and PMut
were used to evaluated nonsynonymous variant.
Sequencing data were deposited in to NIH Short Read
Archive (SRP033329).
Results
The 9-month-old male patient was diagnosed with
DMD. The patient was an only child of his healthy
parents. There was no medical history of note (Fig. 1).
The main complaint of the patient was diarrhea. Physical
examination revealed no obvious signs or symptoms.
Biochemical analyses showed an increased level of creat-
ine phosphokinase (CPK), which indicated that the
patient suffered from muscle damage. Increased alanine
v
Fig. 1 Pedigree analysis. The patient is demarcated in black. The patient
was homozygous for the mutation and his mother who had the same
genotype was a carrier of DMD
Table 2 Results of patient electromyogram
Muscle maxium average unite width
Left rectus femoris mix type
Right rectus femoris mix type
Left biceps mix type
Right biceps mix type
Table 1 Results of patient biochemical test
Parameter Test value Change Reference range
CPK, U/L 12517 ↑ 38–174
ALT, U/L 107 ↑ 9–50
AST, U/L 193 ↑ 15–40
LDH, U/L 773 ↑ 109–245
CPK, creatine phosphokinase
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aminotransferase (ALT) and aspartate aminotransferase
(AST) suggested liver dysfunction. In addition, elevated
LDH revealed tissue damage (Table 1). We also per-
formed electromyogram on the patient, which revealed
that rectus femoris and bicep muscles were showed mix
type when at maximum average unit width (Table 2). Re-
sult of electromyogram suggested myogenic damage.
We used a panel of 131 inherited disease-causing
genes to screen for mutations. Our targeted exome
sequencing reached an average mean depth of 168X with
greater than 97.8% coverage of the targeted regions.
After alignment and bioinformatics analyses, single
nucleotide variants (SNVs) and insertions/deletions
(Indels) were annotated to the exome database, among
which those with MAF >0.005 or homozygosity of >1
were filtered out. The missense variants were discarded
based on tolerant prediction using in silico tools.
Although we failed to detect any point mutation, our
results indicated a potential large duplication in the
DMD gene (Fig. 2).
In order to identify the precise mutation site, we per-
formed MLPA to detect complex rearrangements in the
Fig. 2 Target exome sequencing of the proband. The results indicated there was a potential large duplication in the DMD gene
Fig. 3 MPLA results of the proband. a Normal control. b MPLA identified the patient duplication of exons 4–42, which marked as arrows is a a de
novo mutation
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patient. Results from MLPA analysis showed a novel du-
plication involving exons 4–42 in the DMD gene (Fig. 3).
Since DMD is an X-linked recessive muscle-wasting dis-
ease, pedigree analysis further indicated that the mother
is a carrier of this mutation (Fig. 1). We, then, performed
MLPA analysis on the mother of the patient and identi-
fied that the she does, in fact, have duplication of exons
4–42, the same genotype as the patient (Fig. 4). This
mutated rearrangement has not been previously reported
in the Leiden database (www.dmd.nl), and therefore, the
genotype-phenotype correlation remained unknown.
Discussion
In this study, we described a DMD family with a de novo
duplication of exons 4–42, first suggested by targeted
exome sequencing and subsequently detected by MLPA
analysis. The patient was a 9-month-old male that did
not show any typical characteristics of DMD, such as calf
muscle pseudohypertrophy, Gowers’ sign. Biochemistry
tests showed sharply increased CPK and electromyogram
suggested myogenic damage, which led us to speculate
that the patient suffers from DMD. However, clinical
evidence was not sufficient for a formal diagnosis of
DMD. In addition, increased level of ALT, AST and LDH
suggested liver damage. Therefore, differential diagnosis of
diseases that could lead to liver damage, such as viral
hepatitis and Wilson’s disease, should be investigated. We,
therefore, performed a viral hepatitis serology screen and
tested for ceruloplasmin in serum of the patient. The
results of viral hepatitis serology screen were negative,
which ruled out viral hepatitis. In addition, the level of
ceruloplasmin was normal, which did not support a diag-
nosis of Wilson’s disease.
Genetic testing is the mainstay of diagnosis for DMD
[4]. Despite that MLPA is now the most widely used
technique for identifying duplication in DMD [8],
targeted exome sequencing is prefered when evidence
for a diagnosis of DMD is insufficient and when other
metabolic diseases have not been ruled out. Further-
more, targeted exome sequencing is capable of detecting
subtle mutations in the 79 exons that cannot be detected
by MPLA [3]. In our patient, results from targeted
exome sequencing were suggestive of a potential dupli-
cation in the DMD gene. We then confirmed this finding
using MLPA. A combination of MLPA with targeted ex-
ome sequencing can therefore, be a valuable method for
identifying DMD gene defects.
Dystrophin, as encoded by the DMD gene, is predom-
inantly expressed in skeletal and cardiac muscles [6]. As
a significant component of the dystrophin-glycoprotein
complex (DGC), dystrophin, plays a key role in the con-
traction of sarcomeres [13]. Dystrophin is a structural
protein of 427-kD, consisting of a N-terminal actin bind-
ing domain (ABD1), a central rod region, a cysteine-rich
Fig. 4 MPLA results of the patient’s mother. a Normal control. b The identified mutations in the mother of patient was duplication of exons 4–42,
which were marked as arrows. The patient’s mother was a carrier who had the same mutation
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(CR) globular domain, and a C-terminal tail (CT) [13].
The C-terminus is associated with glycoproteins and the
N-terminus is associated with actin or actin-like proteins
[1]. Previous study suggested that dystrophinis is a cyto-
skeletal protein that is potentially involved in linking the
extracellular matrix to the interior of muscle fibers.
Mutations in the DMD gene, therefore, may disrupt such
linkage and ultimately lead to DMD as a result of sarco-
lemma instability [1]. As the disease progresses, DMD
patient may lose the ability to walk without assistance
and may eventually die from respiratory or cardiac
failure as a result of relative muscle damage [14].
The only pharmacologic agent proven to be effective
for treating DMD is corticosteroids. Long-term studies
indicated that long-term daily administration of cortico-
steroids reduces the decline of cardiorespiratory func-
tion, lowers the risk of progressive scoliosis, prolongs
ambulation by up to 3 years, and improves life expect-
ancy of DMD patients [15–18]. In addition, novel
therapies for DMD, such as stem cell therapy, gene therapy
(e.g. viral vectors), and dystrophin restoration approach,
have recently been developed [4]. In this study, we demon-
strated that a combination of targeted exome sequencing
and MLPA is a valuable diagnostic method for detecting
DMD at the early stage of the disease, which is critical for
early intervention and can ultimately lead to better progno-
sis of DMD patients. If a patient with rapid increase of
CPK, even though does not show any typical characteristics
of DMD, such as calf muscle pseudohypertrophy, Gowers’
sign, we should suspect DMD and consider to perform
Targeted exome sequencing and MLPA.
Conclusions
In summary, our study identified a de novo duplication
of exons 4–42 in the DMD gene in a 9-month-old male
Chinese patient using a combination of targeted exome
sequencing and MLPA. The discovery of this novel
mutation may provide important insights for future
investigations.
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